Maternal Abdominal Morphology Assessment (MAMA) Study

The MAMA study is looking at how the pancreas changes during pregnancy in mothers and their babies, especially when the mother has diabetes. Previous research suggests pancreas size might be smaller in people with diabetes, and that it grows during pregnancy. This study uses magnetic resonance imaging (MRI) to measure these changes. You may be able to join if you are a pregnant woman, aged 18-54, less than 14 weeks pregnant with one baby, and plan to stay in the Austin area for one year after delivery. This is an observational study, meaning there are no interventions or treatments being tested. The study aims to understand how pancreas size relates to gestational diabetes (diabetes during pregnancy) and how a baby's pancreas develops.

Study design
This is an observational study that will follow up to 87 pregnant women and their babies. It is a prospective cohort study, meaning participants are followed over time.
What's involved
You would have study visits at approximately 15-18 weeks, 24-28 weeks, and 34-38 weeks of pregnancy, and again about one year after delivery. These visits include reporting height and weight, blood pressure checks, blood draws, a finger stick test (HbA1c), an oral glucose tolerance test (OGTT), an MRI scan, and continuous glucose monitoring (CGM).
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through pregnancy and for one year to one year and two months postpartum.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06784674

Maternal Abdominal Morphology Assessment

Recruiting
Not specifiedAges 18–54Observational
University of Texas at Austin
~87 participants
Updated 2025-10-22 on ClinicalTrials.gov
What's tested:No intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maternal Pancreatic Volume
Measured over 15-18 weeks gestation, 24-28 weeks gestation, and 34-38 weeks gestation as well as 1 year-1 year and 2 months postpartum.
+1 more outcome measured
Pregnancy Related
Infant Development
Pancreas
Diabetes
1 sites across 1 states
Texas1
  • Jack Virostko, Ph.D. · PRINCIPAL_INVESTIGATOR · University of Texas at Austin

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pregnant women, with a singleton gestation
Age 18 - 54 years at screening
Gestational age \< 14 weeks
Willing to commit to 1 year postpartum follow up
Planning to remain in geographical vicinity of Austin for 1 year after delivery

Exclusion

Presence of any mechanically or magnetically activated implants
Claustrophobia
Other contraindication for MRI
BMI ≥ 38.0 or maximum width less than 48 cm (necessary to fit within the MRI field of view)
  • Maternal Pancreatic Volume15-18 weeks gestation, 24-28 weeks gestation, and 34-38 weeks gestation as well as 1 year-1 year and 2 months postpartum.

    Maternal pancreatic volume will be measured at each study visit. MRI will be utilized to determine maternal pancreatic volume in cm\^3.

  • Fetal Pancreatic Volume15-18 weeks gestation, 24-28 weeks gestation, and 34-38 weeks gestation.

    Fetal pancreatic volume will be measured at each study visit. MRI will be utilized to determine fetal pancreatic volume in utero in cm\^3. Fetal pancreatic volume will not be ascertained at the final study visit.